Picton Mahoney Asset Management Boosts Stock Holdings in Charles River Laboratories International, Inc. $CRL

Picton Mahoney Asset Management grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 126.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,309 shares of the medical research company’s stock after purchasing an additional 43,800 shares during the period. Picton Mahoney Asset Management owned approximately 0.16% of Charles River Laboratories International worth $12,252,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Rothschild Investment LLC raised its holdings in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the period. Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International in the second quarter worth $29,000. Atlantic Union Bankshares Corp bought a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $31,000. Geneos Wealth Management Inc. raised its stake in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the period. Finally, Allworth Financial LP lifted its holdings in Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after purchasing an additional 190 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CRL. Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price for the company in a report on Monday, December 15th. Barclays reduced their price objective on shares of Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, February 19th. Citigroup increased their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Robert W. Baird set a $193.00 price target on shares of Charles River Laboratories International in a research report on Thursday, February 19th. Finally, TD Cowen decreased their price target on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Ten research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $203.57.

Charles River Laboratories International Price Performance

CRL stock opened at $179.97 on Thursday. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $228.88. The company has a market cap of $8.86 billion, a P/E ratio of -60.80, a PEG ratio of 3.00 and a beta of 1.64. The firm has a 50-day moving average of $196.31 and a 200 day moving average of $180.59. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. During the same period last year, the business earned $2.66 EPS. Charles River Laboratories International’s quarterly revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.